Diplomat Pharmacy (DPLO) Tops Q4 EPS by 2c, Slight Miss on Revenues; Offers FY18 EPS Below Consensus, FY18 Revenue Mid-Point Outlook Below Consensus

Diplomat Pharmacy (NYSE: DPLO) reported Q4 EPS of $0.18, $0.02 better than the analyst estimate of $0.16. Revenue for the quarter came in at $1.16 billion versus the consensus estimate of $1.17 billion.

Fourth Quarter 2017 Highlights include:

• Revenue of $1,155 million, compared to $1,145 million
• Total prescriptions dispensed of 248,000, compared to 242,000
• Gross margin of 8.1%, compared to 7.3%
  • Gross profit per prescription dispensed of $353, compared to $342
• Net income (loss) attributable to Diplomat of $6.5 million, compared to $(1.1) million
• Adjusted EBITDA of $26.6 million, compared to $26.1 million
  • Adjusted EBITDA margin of 2.3%, compared to 2.3%
• EPS of $0.09 per diluted common share, compared to $(0.02)
  • Adjusted EPS of $0.18, compared to $0.08

2018 Financial Outlook

For the full-year 2018, we provide financial guidance as follows:

• Revenue between $5.3 and $5.6 billion
• Net income attributable to Diplomat between $4.5 and $13.0 million
• Adjusted EBITDA between $164 and $170 million
• Diluted EPS between $0.06 and $0.17
• Adjusted EPS between $0.87 and $0.97

GUIDANCE:

Diplomat Pharmacy sees FY2018 EPS of $0.87-$0.97, versus the consensus of $1.02. Diplomat Pharmacy sees FY2018 revenue of $5.3-5.6 billion, versus the consensus of $5.42 billion.

For earnings history and earnings-related data on Diplomat Pharmacy (DPLO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance